B+
Bull case
30%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
CTNM
Contineum TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The constructive case is balance-sheet-backed optionality around PIPE-791: patient dosing has started in PROPEL-IPF, chronic-pain topline is due in Q2 2026, and cash runway extends into mid-2029, giving CTNM time to reach more meaningful clinical inflections without obvious near-term financing stress [#PR-2026-03-05][#10-K-2026-03-05].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +8.7.
What can break
Cash runway is improved but not permanent; clinical setbacks could reopen dilution risk.
Momentum
64
Value
41
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $13.00 · Bull $19.00 · Bear $8.00Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $23.43
Why
Momentum64 · Δ7d +2.3
Value41 · Δ7d 0.0
Sentiment51 · Δ7d +8.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +8.7.
Contradictions & invalidation
- • Cash runway is improved but not permanent; clinical setbacks could reopen dilution risk.
- • PIPE-307 optionality is constrained because J&J controls further development decisions.
- • This remains a cautious monitoring story because CTNM is still pre-revenue, concentrated in early-stage PIPE-791 execution, and reliant on uncertain binary readouts; PIPE-307 is partner-controlled by J&J, and the prior RRMS Phase 2 study missed prespecified efficacy endpoints, limiting backup-program visibility [#10-K-2026-03-05].
Catalyst clock
2026-06-30
PIPE-791 chronic pain Phase 1b topline in Q2 2026
Lead driver: Sentiment · See AI snapshot
Momentum
64
9% active weight
Current posture
7d trendImproving
Δ7d
+2.3
Δ21d
-7.7
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
51
62% active weight
Current posture
7d trendImproving
Δ7d
+8.7
Δ21d
-8.7
Why this grade
Composite grade D. Momentum 64.4 / Value 41.2 / Sentiment 50.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$546.64M
Beta
-
Shares Out
37.62M
P/E (TTM) · Derived
-6.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-9.02
Rev YoY
-100.0%
EPS YoY
-34.7%
Gross Margin
+99.6%
Op Margin
-
Net Debt
-$254.65M
Current Ratio
37.17
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data